A Phase 3 interventional study of Ibrutinib and Venetoclax in Mantle-Cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 120 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing venetoclax in Lymphoma, Mantle-Cell — 5 open to participants now, 13 under way, none of them phase 3. venetoclax · Lymphoma, Mantle-Cell.
Among the 23 studies testing venetoclax in Lymphoma, Mantle-Cell, this one has the largest enrollment, is one of 2 that started in 2017, is the only one in phase 3, and was the 4th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →5 of the 23 studies testing venetoclax in Lymphoma, Mantle-Cell are open now, in 3 countries. Recruiting first, the newest first:
The Lymphoma Academic Research Organisation · Sites in Belgium, France
Ages 18–79
Academic and Community Cancer Research United · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–80
Austin I Kim · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 1
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 37 across the 23 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
10 studies in Lymphoma, Mantle-Cell by AbbVie: none open now, 2 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 10 studies in Lymphoma, Mantle-Cell by AbbVie, this one has the largest enrollment, is the only one that started in 2017, is the only one in phase 3, and was the 6th registered.
AbbVie’s Lymphoma, Mantle-Cell studies by the year they started, since 2006.
6 of the studies testing venetoclax in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05861050City of Hope Medical CenterGlofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | 2027-02-01 |
| NCT04939272City of Hope Medical CenterCopanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | 2027-02-12 |
| NCT06522386M.D. Anderson Cancer CenterGATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | 2027-02-28 |
| NCT03710772M.D. Anderson Cancer CenterIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-03-22 |
| NCT03523975City of Hope Medical CenterVenetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | 2027-06-24 |
Add all 6 to your calendar (.ics) → With an account.
Among the 23 studies testing venetoclax in Lymphoma, Mantle-Cell, from their registry updates:
Among AbbVie’s 10 in Lymphoma, Mantle-Cell:
This tab as a report to print or save as PDF → With an account.
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
Arm
Inclusion Criteria:
Exclusion Criteria:
Treatment Naïve Arm
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a low or high risk of TLS enroll into the open-label Safety Run-in Period to receive concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramp up to a target dose of 400 mg once daily over a 5-week period.
Drug: Ibrutinib · Drug: Venetoclax
Participants randomized to ibrutinib and venetoclax for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax is discontinued after 104 weeks of treatment, regardless of response assessment.
Drug: Ibrutinib · Drug: Venetoclax
Participants randomized to ibrutinib and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo is discontinued after 104 weeks of treatment, regardless of response assessment.
Drug: Ibrutinib · Drug: Placebo Oral tablet to match Venetoclax
Participants are treated with ibrutinib 560 mg and venetoclax 400 mg, administered using the 5-week ramp-up schedule.
Drug: Ibrutinib · Drug: Venetoclax
Administered orally once daily
Administered orally once daily
Administered orally once daily
Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
TLS events are defined as follows: * Clinical TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) with the following exceptions: * For the purpose of TLS assessment during the Safety Run-in Period, only those increases in serum creatinine \> 1.0 mg/dL from pre-treatment baseline will be considered clinical TLS. * In participants with renal dysfunction at baseline (CrCl \< 60 mL/min), clinical TLS is defined as the presence of laboratory TLS plus either seizures, cardiac dysrhythmia, or death. * Laboratory TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) for laboratory TLS, that does not resolve within 72 hours despite protocol required management.
Time frame: After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Number of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
DLT: any Grade (Gr) 3 or higher non-TLS adverse event (AE) at least possibly related to study drug occurring during the DLT assessment period with the following clarifications: Non-Hematologic DLTs: Gr ≥3 nausea, vomiting or diarrhea uncontrolled despite maximum medical supportive care and persisting \>5 days; Gr 3 fatigue persisting \>7 days; Gr 3 infection is not a DLT, however an infection with lifethreatening consequences or requiring urgent intervention (Gr 4) was considered a DLT; Treatment delay of any study drug \>7 days for toxicity. Hematologic DLTs: Gr 3 neutropenia is not a DLT, however, Gr 4 neutropenia (ANC \<500/mm\^3) lasting for \> 7 days is a DLT; Gr 3 or 4 neutropenia complicated by fever ≥38.5°C or infection; Gr 4 thrombocytopenia (\<25,000/mm\^3) that persists for \> 7 days; Gr 3 or 4 thrombocytopenia associated with Gr 2 or greater bleeding; Gr 3 anemia is not a DLT, however, Gr 4 anemia is a DLT; Treatment delay of any study drug \>7 days for hematologic toxicity.
Time frame: After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).
Time frame: From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 20.0 months
Progression-free Survival (PFS) (Randomization Phase)
PFS is defined as the time from the date of randomization to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.
Time frame: For an overall median time on study of 61.34 months
Complete Response (CR) Rate (Treatment-Naive Arm)
CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
Time frame: For an overall median time on study of 40.51 months
Overall Survival (OS) (Safety Run-in)
OS is defined as the time from the date of the first dose of study treatment to death from any cause.
Time frame: For an overall median time on study of 74.78 months
Progression-free Survival (PFS) (Safety Run-in)
PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.
Time frame: For an overall median time on study of 74.78 months
Duration of Response (DOR) (Safety Run-in)
DOR is defined for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.
Time frame: For an overall median time on study of 74.78 months
Overall Response Rate (ORR) (Safety Run-in)
ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
Time frame: For an overall median time on study of 74.78 months
Percentage of Participants With a Complete Response (CR) (Randomization Phase)
Complete response rate (CR) based on the best overall response per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
Time frame: For an overall median time on study of 61.34 months
Overall Response Rate (ORR) (Randomization Phase and Treatment-Naive Arm)
ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
MRD-negative Remission Rate in Participants Who Achieve CR Per Investigator Assessment (Randomization Phase and Treatment-Naive Arm)
MRD-negative remission rate is defined as the percentage of participants with undetectable MRD at documented CR in participants who were MRD positive at screening as assessed by flow cytometry in bone marrow and/or peripheral blood, with requirement of confirmation of MRD negativity in the subsequent peripheral blood 12 weeks later.
Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Overall Survival (OS) (Randomization Phase and Treatment-Naive Arm)
OS is defined as the time from the date of randomization (Randomization Phase) or the first dose of study treatment (Treatment-Naïve arm) to death from any cause.
Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Duration of Response (DOR) (Randomization Phase and Treatment-Naive Arm)
DOR is defined as the time frame for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.
Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Time to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm)
TTNT is defined as the duration from the date of randomization (Randomization Phase) or date of first dose of study treatment (Treatment-Naive Arm) to the start date of any anti-lymphoma treatment subsequent to study treatment. Post-treatment stem cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, or other cellular therapies were not considered subsequent anti-cancer treatments for participants responding to the study treatment (CR or PR).
Time frame: For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)
Number of Participants With TEAEs (Randomization Phase)
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).
Time frame: From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 19.5 months
Number of Participants With TLS TEAEs (Randomization Phase)
Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug (SD). Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).
Time frame: From first dose of study drug until the end of treatment + 7 days, with an overall median treatment duration 19.5 months
Steady-State Pharmacokinetics (PK) of Ibrutinib: Maximum Observed Plasma Concentration (Cmax) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Time to Cmax (Tmax) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Terminal Elimination Half-Life (t1/2,Term) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Time of Last Measurable Concentration (Tlast) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From 0-24 Hours (AUC0-24) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Terminal Elimination Rate Constant (λz) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Venetoclax: Cmax (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Venetoclax: AUC0-24 (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Steady-State PK of Venetoclax: CLss/F (Randomization Phase)
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
Time frame: Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose
Time to Worsening in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale of the Health-related Quality of Life (Randomization Phase)
The FACT-Lym lymphoma-specific additional concerns subscale responses to all items are rated on a 5-point scale ranging from 0 "not at all" to 4 "very much". The lymphoma subscale includes 15 items and scores range from 0 to 60, with higher scores representing better functional status and well-being. A 5-point change in the Lym subscale was selected as a conservative estimate of clinically meaningful deterioration in lymphoma symptoms.
Time frame: For an overall median time on study of 61.34 months (Randomization Phase)
Duration of CR (Treatment-Naive Arm)
Duration of CR, defined for subjects who achieve CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014) as the time from the first occurrence of CR to disease progression or death, whichever occurs first.
Time frame: For an overall median time on study of 40.51 months
Progression-free Survival (PFS) (Treatment-Naive Arm)
PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.
Time frame: For an overall median time on study of 40.51 months
| Milestone | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|---|---|
| Started | 15 | 6 | 134 | 133 | 78 |
| On study treatment at study closure | 0 | 2 | 31 | 21 | 26 |
| Off treatment and on study follow up at study closure | 2 | 0 | 22 | 25 | 25 |
| Completed | 2 | 2 | 53 | 46 | 51 |
| Not completed | 13 | 4 | 81 | 87 | 27 |
| Withdrew: Withdrawal by subject | 3 | 0 | 11 | 9 | 7 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 3 | 2 |
| Withdrew: Death | 8 | 3 | 67 | 73 | 18 |
| Withdrew: Other, not specified | 1 | 0 | 1 | 2 | 0 |
TLS events are defined as follows: * Clinical TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) with the following exceptions: * For the purpose of TLS assessment during the Safety Run-in Period, only those increases in serum creatinine \> 1.0 mg/dL from pre-treatment baseline will be considered clinical TLS. * In participants with renal dysfunction at baseline (CrCl \< 60 mL/min), clinical TLS is defined as the presence of laboratory TLS plus either seizures, cardiac dysrhythmia, or death. * Laboratory TLS: any event that meets Howard criteria (N Engl J Med 2011;364:1844-1854) for laboratory TLS, that does not resolve within 72 hours despite protocol required management.
| Participants | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in) | 1 | 0 |
DLT: any Grade (Gr) 3 or higher non-TLS adverse event (AE) at least possibly related to study drug occurring during the DLT assessment period with the following clarifications: Non-Hematologic DLTs: Gr ≥3 nausea, vomiting or diarrhea uncontrolled despite maximum medical supportive care and persisting \>5 days; Gr 3 fatigue persisting \>7 days; Gr 3 infection is not a DLT, however an infection with lifethreatening consequences or requiring urgent intervention (Gr 4) was considered a DLT; Treatment delay of any study drug \>7 days for toxicity. Hematologic DLTs: Gr 3 neutropenia is not a DLT, however, Gr 4 neutropenia (ANC \<500/mm\^3) lasting for \> 7 days is a DLT; Gr 3 or 4 neutropenia complicated by fever ≥38.5°C or infection; Gr 4 thrombocytopenia (\<25,000/mm\^3) that persists for \> 7 days; Gr 3 or 4 thrombocytopenia associated with Gr 2 or greater bleeding; Gr 3 anemia is not a DLT, however, Gr 4 anemia is a DLT; Treatment delay of any study drug \>7 days for hematologic toxicity.
| Participants | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Any TEAE/Any Grade | 3 | 0 |
| Any TEAE/ Grade 3+4 | 3 | 0 |
| Any TEAE/Grade 5 | 0 | 0 |
| Atrial fibrillation/Any Grade | 1 | 0 |
| Atrial fibrillation/Grade 3+4 | 1 | 0 |
| Atrial fibrillation/Grade 5 | 0 | 0 |
| Infection/Any Grade | 1 | 0 |
| Infection/Grade 3+4 | 1 | 0 |
| Infection/Grade 5 | 0 | 0 |
| Neutropenia/Any Grade | 1 | 0 |
| Neutropenia/Grade 3+4 | 1 | 0 |
| Neutropenia/Grade 5 | 0 | 0 |
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).
| Participants | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Any TEAE | 15 | 6 |
| Any TEAE, Grade 3 | 15 | 5 |
| Any Venetoclax (V) Related TEAE | 14 | 6 |
| Any V Related TEAE Grade >=3 | 13 | 4 |
| Any Ibrutinib (I) Related TEAE | 13 | 5 |
| Any I Related TEAE Grade >=3 | 12 | 4 |
| Any TEAE Leading to Discontinuation of Study Drug (I or V) | 6 | 2 |
| Any TEAE Leading to Discontinuation of Study Drug (I only) | 1 | 0 |
| Any TEAE Leading to Discontinuation of Study Drug (V only) | 1 | 0 |
| Any TEAE Leading to Discontinuation of Study Drug (Both I and V) | 4 | 2 |
| Any TEAE Leading to Dose Reduction of Study Drug (I or V) | 7 | 4 |
| Any TEAE Leading to Dose Reduction of Study Drug (I Only) | 1 | 3 |
| Any TEAE Leading to Dose Reduction of Study Drug (V Only) | 3 | 0 |
| Any TEAE Leading to Dose Reduction of Study Drug (Both I and V) | 3 | 1 |
| Any TEAE Leading to Dose Hold of Study Drug (I or V) | 14 | 4 |
| Any TEAE Leading to Dose Hold of Study Drug (I Only) | 1 | 1 |
| Any TEAE Leading to Dose Hold of Study Drug (V Only) | 0 | 0 |
| Any TEAE Leading to Dose Hold of Study Drug (Both I and V) | 13 | 3 |
| Any TESAE | 14 | 3 |
| Any TESAE, Grade >=3 | 14 | 2 |
| Any TESAE, V Related | 9 | 1 |
| Any TESAE, I Related | 10 | 1 |
| Any TESAE, V or I Related | 10 | 1 |
| Fatal TEAE | 1 | 0 |
| Major Hemorrhage | 2 | 0 |
| Major Hemorrhage, Grade >=3 | 2 | 0 |
| Major Hemorrhage, TESAE | 2 | 0 |
PFS is defined as the time from the date of randomization to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.
| months | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Progression-free Survival (PFS) (Randomization Phase) | 31.9 (22.8 to 54.5) | 22.1 (16.5 to 29.5) |
CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
| percentage of participants | Treatment-naive Open-label Arm |
|---|---|
| Complete Response (CR) Rate (Treatment-Naive Arm) | 69.2 (57.8 to 79.2) |
OS is defined as the time from the date of the first dose of study treatment to death from any cause.
| months | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Overall Survival (OS) (Safety Run-in) | 52.3 (14.1 to NA) | NA (1.5 to NA) |
PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.
| months | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Progression-free Survival (PFS) (Safety Run-in) | 46.9 (13.0 to NA) | 35.0 (1.2 to NA) |
DOR is defined for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.
| months | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Duration of Response (DOR) (Safety Run-in) | 44.1 (12.5 to NA) | NA (26.5 to NA) |
ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
| percentage of participants | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline |
|---|---|---|
| Overall Response Rate (ORR) (Safety Run-in) | 80.0 (51.9 to 95.7) | 83.3 (35.9 to 99.6) |
Complete response rate (CR) based on the best overall response per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
| percentage of participants | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Percentage of Participants With a Complete Response (CR) (Randomization Phase) | 53.7 (44.9 to 62.4) | 32.3 (24.5 to 41.0) |
ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).
| percentage of participants | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|
| Overall Response Rate (ORR) (Randomization Phase and Treatment-Naive Arm) | 82.1 (74.5 to 88.2) | 74.4 (66.2 to 81.6) | 94.9 (87.4 to 98.6) |
MRD-negative remission rate is defined as the percentage of participants with undetectable MRD at documented CR in participants who were MRD positive at screening as assessed by flow cytometry in bone marrow and/or peripheral blood, with requirement of confirmation of MRD negativity in the subsequent peripheral blood 12 weeks later.
| percentage of participants | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|
| Bone marrow aspirate | 61.5 (40.6 to 79.8) | 28.6 (3.7 to 71.0) | 59.1 (36.4 to 79.3) |
| Peripheral blood | 77.4 (58.9 to 90.4) | 12.5 (0.3 to 52.7) | 76.5 (58.8 to 89.3) |
OS is defined as the time from the date of randomization (Randomization Phase) or the first dose of study treatment (Treatment-Naïve arm) to death from any cause.
| months | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|
| Overall Survival (OS) (Randomization Phase and Treatment-Naive Arm) | 44.9 (31.9 to NA) | 38.6 (25.2 to 52.6) | NA (44.2 to NA) |
DOR is defined as the time frame for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \[Cheson 2014\]) to disease progression or death, whichever occurs first.
| months | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|
| Duration of Response (DOR) (Randomization Phase and Treatment-Naive Arm) | 42.1 (28.7 to NA) | 27.6 (19.4 to 39.5) | 37.1 (30.3 to NA) |
TTNT is defined as the duration from the date of randomization (Randomization Phase) or date of first dose of study treatment (Treatment-Naive Arm) to the start date of any anti-lymphoma treatment subsequent to study treatment. Post-treatment stem cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, or other cellular therapies were not considered subsequent anti-cancer treatments for participants responding to the study treatment (CR or PR).
| months | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|
| Time to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm) | NA (48.0 to NA) | 35.4 (24.7 to 49.8) | NA (NA to NA) |
AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with treatment. The investigator assesses the relationship of each event to the use of study. Serious adverse event (SAE): an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug. Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).
| Participants | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Any TEAE | 134 | 131 |
| Any TEAE, Grade 3 | 113 | 100 |
| Any Venetoclax (V) Related TEAE | 112 | 104 |
| Any V Related TEAE Grade >=3 | 75 | 46 |
| Any Ibrutinib (I) Related TEAE | 121 | 114 |
| Any I Related TEAE Grade >=3 | 83 | 58 |
| Any TEAE Leading to Discontinuation of Study Drug (I or V) | 43 | 48 |
| Any TEAE Leading to Discontinuation of Study Drug (I only) | 15 | 11 |
| Any TEAE Leading to Discontinuation of Study Drug (V only) | 2 | 7 |
| Any TEAE Leading to Discontinuation of Study Drug (Both I and V) | 26 | 30 |
| Any TEAE Leading to Dose Reduction of Study Drug (I or V) | 50 | 29 |
| Any TEAE Leading to Dose Reduction of Study Drug (I Only) | 19 | 14 |
| Any TEAE Leading to Dose Reduction of Study Drug (V Only) | 13 | 7 |
| Any TEAE Leading to Dose Reduction of Study Drug (Both I and V) | 18 | 8 |
| Any TEAE Leading to Dose Hold of Study Drug (I or V) | 106 | 99 |
| Any TEAE Leading to Dose Hold of Study Drug (I Only) | 18 | 18 |
| Any TEAE Leading to Dose Hold of Study Drug (V Only) | 6 | 4 |
| Any TEAE Leading to Dose Hold of Study Drug (Both I and V) | 82 | 77 |
| Any TESAE | 88 | 80 |
| Any TESAE, Grade >=3 | 76 | 73 |
| Any TESAE, V Related | 31 | 25 |
| Any TESAE, I Related | 47 | 37 |
| Any TESAE, V or I Related | 49 | 37 |
| Fatal TEAE | 22 | 18 |
| Major Hemorrhage | 13 | 8 |
| Major Hemorrhage, Grade >=3 | 10 | 7 |
| Major Hemorrhage, TESAE | 12 | 6 |
Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs): any event that began or worsened in severity on or after the first dose of study drug (SD). Event severity is graded as mild (1), moderate (2), severe (3), life threatening (4), death (5).
| Participants | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Any Grade | 7 | 3 |
| Grades 3 and 4 | 6 | 3 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| ng/mL | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State Pharmacokinetics (PK) of Ibrutinib: Maximum Observed Plasma Concentration (Cmax) (Randomization Phase) | 195 ± 179 | 287 ± 230 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| hours | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Time to Cmax (Tmax) (Randomization Phase) | 2.00 (0.00 to 8.00) | 2.00 (0.750 to 6.00) |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| ng·h/mL | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Randomization Phase) | 1090 ± 870 | 1440 ± 1060 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| hours | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Terminal Elimination Half-Life (t1/2,Term) (Randomization Phase) | 6.29 ± 1.92 | 6.66 ± 2.15 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| hours | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Time of Last Measurable Concentration (Tlast) (Randomization Phase) | 24.0 (7.0 to 24.0) | 24.0 (24.0 to 24.0) |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| ng·h/mL | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Area Under the Concentration-Time Curve From 0-24 Hours (AUC0-24) (Randomization Phase) | 1090 ± 870 | 1440 ± 1060 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| 1/hour | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Terminal Elimination Rate Constant (λz) (Randomization Phase) | 0.123 ± 0.0556 | 0.114 ± 0.0332 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| L/hour | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Steady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase) | 1020 ± 1130 | 709 ± 651 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| ng/mL | Randomization Phase: Ibrutinb + Venetoclax |
|---|---|
| Steady-State PK of Venetoclax: Cmax (Randomization Phase) | 3620 ± 1650 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| ng·h/mL | Randomization Phase: Ibrutinb + Venetoclax |
|---|---|
| Steady-State PK of Venetoclax: AUC0-24 (Randomization Phase) | 65000 ± 32900 |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| hours | Randomization Phase: Ibrutinb + Venetoclax |
|---|---|
| Steady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase) | 6.00 (0.00 to 8.03) |
Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.
| L/hour | Randomization Phase: Ibrutinb + Venetoclax |
|---|---|
| Steady-State PK of Venetoclax: CLss/F (Randomization Phase) | 8.09 ± 4.82 |
The FACT-Lym lymphoma-specific additional concerns subscale responses to all items are rated on a 5-point scale ranging from 0 "not at all" to 4 "very much". The lymphoma subscale includes 15 items and scores range from 0 to 60, with higher scores representing better functional status and well-being. A 5-point change in the Lym subscale was selected as a conservative estimate of clinically meaningful deterioration in lymphoma symptoms.
| months | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo |
|---|---|---|
| Time to Worsening in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale of the Health-related Quality of Life (Randomization Phase) | 9.3 (6.5 to 12.7) | 12.5 (8.3 to 17.9) |
Duration of CR, defined for subjects who achieve CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014) as the time from the first occurrence of CR to disease progression or death, whichever occurs first.
| months | Treatment-naive Open-label Arm |
|---|---|
| Duration of CR (Treatment-Naive Arm) | 37.1 (34.0 to NA) |
PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.
| months | Treatment-naive Open-label Arm |
|---|---|
| Progression-free Survival (PFS) (Treatment-Naive Arm) | 40.2 (29.4 to NA) |
Collected over For an overall median duration of 69.6 months (Safety Run-in: Increased TLS Risk), 77.9 months (Safety Run-in: Low TLS Risk), 61.0 months (Randomization Phase: Ibrutinb + Venetoclax), 61.7 months (Randomization Phase: Ibrutinb + Placebo), 40.5 months (Treatment-naive Open-label Arm).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-in: Increased TLS Risk at Baseline | 8/15 (53.3%) | 15/15 (100%) | 15/15 (100%) |
| Safety Run-in: Low TLS Risk at Baseline | 3/6 (50%) | 3/6 (50%) | 6/6 (100%) |
| Randomization Phase: Ibrutinb + Venetoclax | 70/134 (52.2%) | 92/134 (68.7%) | 131/134 (97.8%) |
| Randomization Phase: Ibrutinib + Placebo | 78/132 (59.1%) | 86/132 (65.2%) | 127/132 (96.2%) |
| Treatment-naive Open-label Arm | 20/78 (25.6%) | 48/78 (61.5%) | 77/78 (98.7%) |
| Event | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|---|---|
| PYREXIAGeneral disorders | 3/15 | 0/6 | 1/134 | 1/132 | 3/78 |
| PANCYTOPENIABlood and lymphatic system disorders | 0/15 | 1/6 | 2/134 | 0/132 | 0/78 |
| RETROPERITONEAL HAEMORRHAGEGastrointestinal disorders | 0/15 | 1/6 | 0/134 | 0/132 | 0/78 |
| CELLULITISInfections and infestations | 0/15 | 1/6 | 1/134 | 2/132 | 2/78 |
| STAPHYLOCOCCAL BACTERAEMIAInfections and infestations | 0/15 | 1/6 | 1/134 | 0/132 | 0/78 |
| ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications | 0/15 | 1/6 | 7/134 | 2/132 | 1/78 |
| FALLInjury, poisoning and procedural complications | 2/15 | 1/6 | 1/134 | 2/132 | 1/78 |
| SPLENIC RUPTUREInjury, poisoning and procedural complications | 0/15 | 1/6 | 0/134 | 0/132 | 0/78 |
| MANTLE CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/15 | 0/6 | 15/134 | 18/132 | 1/78 |
| ANAEMIABlood and lymphatic system disorders | 2/15 | 0/6 | 6/134 | 2/132 | 0/78 |
| Event | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm |
|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 10/15 | 5/6 | 84/134 | 48/132 | 37/78 |
| NAUSEAGastrointestinal disorders | 5/15 | 5/6 | 43/134 | 21/132 | 24/78 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 4/15 | 4/6 | 22/134 | 20/132 | 8/78 |
| FATIGUEGeneral disorders | 5/15 | 4/6 | 39/134 | 36/132 | 30/78 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 3/15 | 4/6 | 14/134 | 4/132 | 16/78 |
| INCREASED TENDENCY TO BRUISEBlood and lymphatic system disorders | 3/15 | 3/6 | 12/134 | 10/132 | 17/78 |
| VISION BLURREDEye disorders | 4/15 | 3/6 | 25/134 | 23/132 | 8/78 |
| DYSPEPSIAGastrointestinal disorders | 1/15 | 3/6 | 19/134 | 11/132 | 8/78 |
| OEDEMA PERIPHERALGeneral disorders | 2/15 | 3/6 | 16/134 | 21/132 | 14/78 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 3/15 | 3/6 | 22/134 | 23/132 | 12/78 |
| Age, Categorical(Participants) | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 5 | 41 | 47 | 13 | 108 |
| >=65 years | 13 | 1 | 93 | 86 | 65 | 258 |
| Sex: Female, Male(Participants) | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 2 | 31 | 25 | 25 | 89 |
| Male | 9 | 4 | 103 | 108 | 53 | 277 |
| Ethnicity (NIH/OMB)(Participants) | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 8 | 7 | 1 | 17 |
| Not Hispanic or Latino | 11 | 5 | 112 | 110 | 72 | 310 |
| Unknown or Not Reported | 3 | 1 | 14 | 16 | 5 | 39 |
| Race (NIH/OMB)(Participants) | Safety Run-in: Increased TLS Risk at Baseline | Safety Run-in: Low TLS Risk at Baseline | Randomization Phase: Ibrutinb + Venetoclax | Randomization Phase: Ibrutinib + Placebo | Treatment-naive Open-label Arm | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 3 | 6 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 1 | 3 |
| White | 12 | 6 | 116 | 115 | 68 | 317 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 15 | 14 | 3 | 35 |
Showing the first 100 of 120 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Jun 2024, 84 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 84 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax